Aardvark Therapeutics Inc (AARD)

$4.30 +0.21 (5.13%)
Market Cap 93.81M
Revenue (ttm) 0.00
Net Income (ttm) -57.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 134,700
Avg Vol 312,126
Day's Range N/A - N/A
Shares Out 21.82M
Stochastic %K 100%
Beta 5.33
Analysts Strong Sell
Price Target $16.90

Company Profile

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 858 225 7696
Address:
4370 La Jolla Village Drive, Suite 1050, San Diego, United States
GlobalMarketBulletin
GlobalMarketBulletin Mar. 29 at 9:09 AM
$AARD Aardvark Therapeutics (NASDAQ: AARD) halted its Phase 3 trial, but the real story may be what comes next. Could this pause unlock a smarter path forward? https://globalmarketbulletin.com/is-aardvark-therapeutics-aard-a-smart-long-term-buy/
0 · Reply
GlobalMarketBulletin
GlobalMarketBulletin Mar. 29 at 8:29 AM
$AARD $AGL $ALLO $HUMA $RZLV These 5 penny stocks are quietly building momentum with breakthrough catalysts, AI expansion, biotech innovation, and massive upside potential. Discover why investors are hunting for the next 10x to 100x opportunities before the crowd catches on. https://globalmarketbulletin.com/top-5-penny-stocks-that-could-turn-1000-into-1-million/
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 27 at 4:45 PM
$AARD RSI: 13.57, MACD: -1.8276 Vol: 0.84, MA20: 4.90, MA50: 9.95 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
RobisonCD1
RobisonCD1 Mar. 26 at 8:30 PM
$AARD In at $3.50 looking for $4+, majorly oversold
0 · Reply
Woooehoo
Woooehoo Mar. 25 at 11:32 PM
$AARD how low does this go, $1?
0 · Reply
_MoonNinja
_MoonNinja Mar. 24 at 2:23 PM
$AARD Major red flag: Phase 3 trial paused
0 · Reply
DonCorleone77
DonCorleone77 Mar. 23 at 11:27 PM
$APO $BARK $BNGO $CLB $AARD AFTER-HOURS MOVERS: Currently Higher After Earnings: - BARK (BARK) up 9.5% - Bionano Genomics (BNGO) up 2.1% Currently Lower After Earnings/Guidance: - Core Laboratories (CLB) down 4.6% after Q1 pre-announcement - Aardvark Therapeutics (AARD) down 1.5% Currently Also Lower: - Comtech Telecommunications (CMTL) down 0.6% after equity offering - Apollo Global Management (APO) down 2.6% after Bloomberg report of capped private equity redemptions
0 · Reply
ScamBuster0
ScamBuster0 Mar. 23 at 8:45 PM
$AARD See https://www.stocktwits.com/ScamBuster0/message/646519282. I was 100% correct according to the Q4 report today. The question of why these incompetent fools running the show didn't do a proper PK mass balance study BEFORE raising the dose to 800mg BID is beyond comprehension. In my opinion, this is shareholder fraud. This management and Board cannot be trusted with public shareholder money. This isn't a drug problem, it's completely an execution problem. And the reason why most biotech/pharmas fail is due to execution.
0 · Reply
RobisonCD1
RobisonCD1 Mar. 23 at 5:08 PM
$AARD Back to $4.50+ and then $5+
0 · Reply
Messerschmittbf109
Messerschmittbf109 Mar. 18 at 6:53 PM
$AARD new TP 6 $ 7$ no upside
0 · Reply
Latest News on AARD
Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Mar 23, 2026, 4:05 PM EDT - 12 days ago

Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Aardvark Therapeutics, Inc. Investigated by the Portnoy Law Firm

Mar 11, 2026, 9:00 AM EDT - 25 days ago

Aardvark Therapeutics, Inc. Investigated by the Portnoy Law Firm

AARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Mar 4, 2026, 10:21 AM EST - 4 weeks ago

AARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

What's Going On With Aardvark Therapeutics Stock On Wednesday?

Mar 4, 2026, 8:54 AM EST - 4 weeks ago

What's Going On With Aardvark Therapeutics Stock On Wednesday?

Why Is Aardvark Therapeutics Stock Sinking Monday?

Mar 2, 2026, 7:02 AM EST - 4 weeks ago

Why Is Aardvark Therapeutics Stock Sinking Monday?

AARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation With the Schall Law Firm

Feb 28, 2026, 11:46 AM EST - 5 weeks ago

AARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation With the Schall Law Firm

Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome

Feb 27, 2026, 4:05 PM EST - 5 weeks ago

Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 13, 2026, 8:00 AM EST - 7 weeks ago

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer

Feb 12, 2026, 8:00 AM EST - 7 weeks ago

Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer

Aardvark Therapeutics Announces Leadership Appointments

Feb 12, 2026, 8:00 AM EST - 7 weeks ago

Aardvark Therapeutics Announces Leadership Appointments

Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome

Feb 10, 2026, 8:00 AM EST - 7 weeks ago

Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome

Aardvark's Hunger Suppressing Drug Candidate Could Potentially Address Massive $10 Billion Market: Analyst

Dec 12, 2025, 2:04 PM EST - 4 months ago

Aardvark's Hunger Suppressing Drug Candidate Could Potentially Address Massive $10 Billion Market: Analyst

Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome

Dec 10, 2025, 4:05 PM EST - 4 months ago

Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome

Aardvark Therapeutics to Present at Upcoming Investor Conferences in December

Nov 25, 2025, 4:05 PM EST - 4 months ago

Aardvark Therapeutics to Present at Upcoming Investor Conferences in December

Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates

Nov 13, 2025, 4:05 PM EST - 5 months ago

Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates

Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Nov 11, 2025, 4:05 PM EST - 5 months ago

Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025

Nov 4, 2025, 12:00 PM EST - 5 months ago

Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Nov 3, 2025, 5:55 PM EST - 5 months ago

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Aardvark Therapeutics to Present at Upcoming Investor Conferences in November

Nov 3, 2025, 8:00 AM EST - 5 months ago

Aardvark Therapeutics to Present at Upcoming Investor Conferences in November

Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek

Oct 22, 2025, 8:00 AM EDT - 5 months ago

Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek

Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome

Oct 8, 2025, 8:00 AM EDT - 6 months ago

Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome

Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum

Sep 23, 2025, 4:05 PM EDT - 6 months ago

Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum

Aardvark Therapeutics, Inc. (AARD) Presents At Cantor Fitzgerald Global Healthcare Conference 2025 Transcript

Sep 4, 2025, 1:25 AM EDT - 7 months ago

Aardvark Therapeutics, Inc. (AARD) Presents At Cantor Fitzgerald Global Healthcare Conference 2025 Transcript

Aardvark Therapeutics to Present at Upcoming Investor Conferences in September

Aug 27, 2025, 4:10 PM EDT - 7 months ago

Aardvark Therapeutics to Present at Upcoming Investor Conferences in September

Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates

Aug 13, 2025, 4:10 PM EDT - 8 months ago

Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates

Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy

Aug 12, 2025, 8:00 AM EDT - 8 months ago

Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy

Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

Jul 18, 2025, 8:00 AM EDT - 9 months ago

Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference

Jun 24, 2025, 8:00 AM EDT - 10 months ago

Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference

Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions

May 19, 2025, 4:10 PM EDT - 11 months ago

Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions

Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 14, 2025, 4:10 PM EDT - 11 months ago

Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

Aardvark Therapeutics to Present at Upcoming Investor Conferences in May

May 7, 2025, 4:05 PM EDT - 11 months ago

Aardvark Therapeutics to Present at Upcoming Investor Conferences in May

Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights

Mar 31, 2025, 4:10 PM EDT - 1 year ago

Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights

U.S. IPO Weekly Recap: Big Listings Post Mixed Results In Busy 7 IPO Week

Feb 14, 2025, 11:50 PM EST - 1 year ago

U.S. IPO Weekly Recap: Big Listings Post Mixed Results In Busy 7 IPO Week

AGH KMTS KRMN NPB ODYS SAIL XHLD

Aardvark Therapeutics Announces Pricing of Initial Public Offering

Feb 12, 2025, 10:38 PM EST - 1 year ago

Aardvark Therapeutics Announces Pricing of Initial Public Offering

U.S. IPO Weekly Recap: Cement And Cystic Fibrosis Drugs Lead A 6 IPO Week

Feb 8, 2025, 2:30 AM EST - 1 year ago

U.S. IPO Weekly Recap: Cement And Cystic Fibrosis Drugs Lead A 6 IPO Week

AGH FBGL HCAI KRMN NPB ODYS PLUT

Aardvark Therapeutics Starts $100 Million IPO Effort For Hunger Treatments

Feb 3, 2025, 11:52 AM EST - 1 year ago

Aardvark Therapeutics Starts $100 Million IPO Effort For Hunger Treatments

GlobalMarketBulletin
GlobalMarketBulletin Mar. 29 at 9:09 AM
$AARD Aardvark Therapeutics (NASDAQ: AARD) halted its Phase 3 trial, but the real story may be what comes next. Could this pause unlock a smarter path forward? https://globalmarketbulletin.com/is-aardvark-therapeutics-aard-a-smart-long-term-buy/
0 · Reply
GlobalMarketBulletin
GlobalMarketBulletin Mar. 29 at 8:29 AM
$AARD $AGL $ALLO $HUMA $RZLV These 5 penny stocks are quietly building momentum with breakthrough catalysts, AI expansion, biotech innovation, and massive upside potential. Discover why investors are hunting for the next 10x to 100x opportunities before the crowd catches on. https://globalmarketbulletin.com/top-5-penny-stocks-that-could-turn-1000-into-1-million/
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 27 at 4:45 PM
$AARD RSI: 13.57, MACD: -1.8276 Vol: 0.84, MA20: 4.90, MA50: 9.95 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
RobisonCD1
RobisonCD1 Mar. 26 at 8:30 PM
$AARD In at $3.50 looking for $4+, majorly oversold
0 · Reply
Woooehoo
Woooehoo Mar. 25 at 11:32 PM
$AARD how low does this go, $1?
0 · Reply
_MoonNinja
_MoonNinja Mar. 24 at 2:23 PM
$AARD Major red flag: Phase 3 trial paused
0 · Reply
DonCorleone77
DonCorleone77 Mar. 23 at 11:27 PM
$APO $BARK $BNGO $CLB $AARD AFTER-HOURS MOVERS: Currently Higher After Earnings: - BARK (BARK) up 9.5% - Bionano Genomics (BNGO) up 2.1% Currently Lower After Earnings/Guidance: - Core Laboratories (CLB) down 4.6% after Q1 pre-announcement - Aardvark Therapeutics (AARD) down 1.5% Currently Also Lower: - Comtech Telecommunications (CMTL) down 0.6% after equity offering - Apollo Global Management (APO) down 2.6% after Bloomberg report of capped private equity redemptions
0 · Reply
ScamBuster0
ScamBuster0 Mar. 23 at 8:45 PM
$AARD See https://www.stocktwits.com/ScamBuster0/message/646519282. I was 100% correct according to the Q4 report today. The question of why these incompetent fools running the show didn't do a proper PK mass balance study BEFORE raising the dose to 800mg BID is beyond comprehension. In my opinion, this is shareholder fraud. This management and Board cannot be trusted with public shareholder money. This isn't a drug problem, it's completely an execution problem. And the reason why most biotech/pharmas fail is due to execution.
0 · Reply
RobisonCD1
RobisonCD1 Mar. 23 at 5:08 PM
$AARD Back to $4.50+ and then $5+
0 · Reply
Messerschmittbf109
Messerschmittbf109 Mar. 18 at 6:53 PM
$AARD new TP 6 $ 7$ no upside
0 · Reply
KOWALSK1
KOWALSK1 Mar. 16 at 7:57 AM
$AARD ✅️ BUY ZONE: 5.00 to 4.74 ✋️ RISK BELOW: 4.23 💲PT.: 5.52 5.80 6.00 6.46 6.77 + UP Follow for more 📣📝
0 · Reply
badarchitect
badarchitect Mar. 9 at 1:40 PM
$AARD Run it
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Mar. 6 at 4:13 PM
$AARD Nice!
0 · Reply
ColoradoKid85
ColoradoKid85 Mar. 6 at 3:10 AM
$AARD given how the stated facts for the pause, the trial is likely to resume, although if it does it will take time.
0 · Reply
DanRom_9
DanRom_9 Mar. 5 at 5:28 PM
$AARD microcap structure extremely quiet if volume ignites move could expand quickly
0 · Reply
ThijsdeMoor
ThijsdeMoor Mar. 5 at 3:46 PM
$AARD
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Mar. 5 at 3:04 PM
$AARD Another overnight swing winner... No losses today.. 39 straight winners.. I love u 🚨🚨
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Mar. 5 at 2:32 PM
$AARD $5.75 To break for more... Go baby go 🚨🚨
0 · Reply
Rounderssss4
Rounderssss4 Mar. 4 at 7:54 PM
$BATL 👀s on $AARD moving need a move like $ASNS or $DXST
0 · Reply
Rounderssss4
Rounderssss4 Mar. 4 at 6:58 PM
$AARD not a lot of shares here so doesn't take much to move a few bucks 😂
0 · Reply
Rounderssss4
Rounderssss4 Mar. 4 at 6:56 PM
$AARD inside buys coming in? Or shorts covering
0 · Reply
Marcoseneg
Marcoseneg Mar. 4 at 9:29 AM
$AARD rebounce today likely
0 · Reply